Shared on 04 Nov 25
Fair value Increased 1.50%Analysts have raised their price target for Cencora by $5 to $338.29. They cite updated forecasts for slightly lower near-term revenue growth, but a stronger overall fair value assessment.
Shared on 04 Sep 25
Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery
With both Cencora’s net profit margin and consensus revenue growth forecasts holding steady, analysts have maintained their price target unchanged at $333.29. What's in the News Cencora completed the repurchase of 4,895,419 shares (2.49% of shares outstanding) for $1,118.1 million under its buyback program announced in May 2024; no shares were repurchased from April to June 2025.
Shared on 07 May 25
Fair value Increased 9.57%Digital Infrastructure And Specialty Services Will Redefine Healthcare Delivery
Shared on 30 Apr 25
Fair value Increased 0.84%US And European 3PL Integration Will Advance Pharmaceutical Networks
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Increased 0.80%US And European 3PL Integration Will Advance Pharmaceutical Networks
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 16 Apr 25
Fair value Increased 3.73%US And European 3PL Integration Will Advance Pharmaceutical Networks
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 0.38%US And European 3PL Integration Will Advance Pharmaceutical Networks
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 2.88%US And European 3PL Integration Will Advance Pharmaceutical Networks
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
US And European 3PL Integration Will Advance Pharmaceutical Networks
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Increased 0.55%US And European 3PL Integration Will Advance Pharmaceutical Networks
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Decreased 14%US And European 3PL Integration Will Advance Pharmaceutical Networks
AnalystConsensusTarget made no meaningful changes to valuation assumptions.